For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 0 |
| Research and development | 413,000 | 1,376,000 | 634,000 | 363,000 |
| Selling, general and administrative | 2,435,000 | 4,219,000 | 2,748,000 | 1,150,000 |
| Loss from operations | -2,848,000 | -5,595,000 | -3,382,000 | -1,513,000 |
| Gain on settlement of vendor payable | - | 249,500* | - | - |
| Other | - | -312,000* | - | 156,000 |
| Unrealized gain on short-term investments | - | - | - | 0 |
| Interest income | 67,000 | 17,000 | 36,000 | 38,000 |
| Interest expense | 63,000 | 31,750* | - | - |
| Loss on initial recognition of greenshoe rights liability | - | 20,209,000* | - | - |
| Gain on settlement of vendor payable | - | - | - | 0 |
| Change in fair value of greenshoe rights liability | - | -2,853,250* | - | - |
| Change in fair value of warrant liability | -11,000 | 3,000 | -232,000 | 114,000 |
| Total other income, net | 15,000 | -17,436,000 | 268,000 | 80,000 |
| Net loss | -2,833,000 | -23,031,000 | -3,114,000 | -1,433,000 |
| Dividend on series l preferred stock | - | -80,000* | - | - |
| Dividend on preferred stock | 103,000 | - | - | - |
| Deemed dividend | 433,000 | -5,786,000* | 144,000 | 85,000 |
| Net loss attributable to common stockholders | -3,369,000 | -28,897,000 | -3,258,000 | -1,518,000 |
| Basic EPS | -0.11 | -5.241 | -0.83 | -0.55 |
| Diluted EPS | -0.11 | -5.241 | -0.83 | -0.55 |
| Basic Average Shares | 30,283,031 | 5,513,255* | 3,940,714 | 2,771,765 |
| Diluted Average Shares | 30,283,031 | 5,513,255* | 3,940,714 | 2,771,765 |
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)